Cellectis Priced, Nasdaq: CLLS

Developing cancer immunotherapies based on gene-edited CAR T cells.

Industry: Health Care

Latest Trade: $22.02 0.00 (0.0%)

First Day Return: -5.3%

Return from IPO: -46.9%

Industry: Health Care

We are a pioneering gene-editing company, employing our core proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology. Our product candidates, based on gene-edited T-cells that express chimeric antigen receptors, seek to harness the power of the immune system to target and eradicate cancers. We believe that CAR-based immunotherapy is one of the most promising areas of cancer research, representing a new paradigm for cancer treatment. We are designing next-generation immunotherapies that are based on gene-edited CAR T-cells. Our gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves. We believe that the allogeneic production of CAR T-cells will allow us to develop cost-effective, “off-the-shelf” products that are capable of being stored and distributed worldwide. Our gene-editing expertise also enables us to develop product candidates that feature additional safety and efficacy attributes, including control properties designed to prevent them from attacking healthy tissues, to enable them to tolerate standard oncology treatments, and to equip them to resist mechanisms that inhibit immune-system activity. In addition to our focus on immuno-oncology, we are exploring the use of our gene-editing technologies in other therapeutic applications, as well as to develop healthier food products for a growing population.
more less
IPO News for Cellectis
more
IPO Data
IPO File Date 02/20/2015
Offer Price $41.50
Price Range $41.50 - $41.50
Offer Shares (mm) 5.5
Deal Size ($mm) $228
IPO Data
IPO Date 03/24/2015
Offer Price $41.50
Price Range $41.50 - $41.50
Offer Shares (mm) 5.5
Deal Size ($mm) $228
Underwriters
more
Company Data
Headquarters Paris, France
Founded 2000
Employees 93
Website www.cellectis.com